p53‐Dependent Mitochondrial Compensation in Heart Failure With Preserved Ejection Fraction

p53‐Dependent Mitochondrial Compensation in Heart Failure With Preserved Ejection Fraction

Background Heart failure with preserved ejection fraction (HFpEF) accounts for 50% of patients with heart failure. Clinically, HFpEF prevalence shows age and gender biases. Although the majority of patients with HFpEF are elderly, there is an emergence of young patients with HFpEF. A better understa...

Descripció completa

Dades bibliogràfiques
Autors principals:	Xiaonan Chen, Hao Lin, Weiyao Xiong, Jianan Pan, Shuying Huang, Shan Xu, Shufang He, Ming Lei, Alex Chia Yu Chang, Huili Zhang
Format:	Article
Idioma:	English
Publicat:	Wiley 2022-06-01
Col·lecció:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Matèries:	aging HFpEF mitochondrial homeostasis p53 activation
Accés en línia:	https://www.ahajournals.org/doi/10.1161/JAHA.121.024582

Ítems similars

The role of coronary microvascular dysfunction in the pathogenesis of heart failure with preserved ejection fraction
per: Becker Al-Khayatt, et al.
Publicat: (2024-05-01)

Impact of severe obesity on exercise performance in heart failure with preserved ejection fraction
per: Satyam Sarma, et al.
Publicat: (2020-11-01)

iNOS contributes to heart failure with preserved ejection fraction through mitochondrial dysfunction and Akt S-nitrosylation
per: Yongzheng Guo, et al.
Publicat: (2023-01-01)

Distinct implications of body mass index in different subgroups of nonobese patients with heart failure with preserved ejection fraction: a latent class analysis of data from the TOPCAT trial
per: Bin Dong, et al.
Publicat: (2022-11-01)

The role of cardiac magnetic resonance imaging in the assessment of heart failure with preserved ejection fraction
per: Clement Lau, et al.
Publicat: (2022-07-01)

Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction
per: Ahmed Hamam, et al.
Publicat: (2022-12-01)

Prognostic significance of the HFA‐PEFF score in patients with heart failure with preserved ejection fraction
per: Yohei Sotomi, et al.
Publicat: (2021-06-01)

Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction
per: Elisabeth A. Jalink, et al.
Publicat: (2024-01-01)

Effects of Continuous Accelerated Pacing on Cardiac Structure and Function in Patients With Heart Failure With Preserved Ejection Fraction: Insights From the myPACE Randomized Clinical Trial
per: Kramer J. Wahlberg, et al.
Publicat: (2024-01-01)

Diagnostic signature for heart failure with preserved ejection fraction (HFpEF): a machine learning approach using multi-modality electronic health record data
per: Nazli Farajidavar, et al.
Publicat: (2022-12-01)

Proteomics and Precise Exercise Phenotypes in Heart Failure With Preserved Ejection Fraction: A Pilot Study
per: Ravi V. Shah, et al.
Publicat: (2023-11-01)

Myocardial RNA Sequencing Reveals New Potential Therapeutic Targets in Heart Failure with Preserved Ejection Fraction
per: José M. Inácio, et al.
Publicat: (2023-07-01)

Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature
per: Alberto Palazzuoli, et al.
Publicat: (2023-01-01)

Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA‐HFpEF trial
per: Mariëlle Scheffer, et al.
Publicat: (2020-12-01)

Right Ventricular‐Vascular Uncoupling Predicts Pulmonary Hypertension in Clinically Diagnosed Heart Failure With Preserved Ejection Fraction
per: Zheng‐Wei Chen, et al.
Publicat: (2024-01-01)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
per: Arjun K. Pandey, et al.
Publicat: (2022-04-01)

Inflammation as a therapeutic target in heart failure with preserved ejection fraction
per: Zhen Hui Peh, et al.
Publicat: (2023-06-01)

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
per: Mark Sweeney, et al.
Publicat: (2020-09-01)

The clinical relevance of quality of life in heart failure patients with preserved ejection fraction
per: Masahiro Seo, et al.
Publicat: (2023-04-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): A Case Report
per: Amanda Halimi, et al.
Publicat: (2021-09-01)

Myths and Facts About Heart Failure with Preserved Ejection Fraction: Risk Factors, Longevity, Potential Pharmacological and Exercise Interventions
per: Chung-Lieh Hung, et al.
Publicat: (2013-03-01)

Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis
per: Domenico D'Amario, et al.
Publicat: (2024-08-01)

Astragaloside IV alleviates inflammation and improves myocardial metabolism in heart failure mice with preserved ejection fraction
per: Xiao Wang, et al.
Publicat: (2024-11-01)

Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta‐analysis
per: Shu Li, et al.
Publicat: (2023-08-01)

Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction
per: Dan Yin, et al.
Publicat: (2023-04-01)

Large Animal Models of Heart Failure: Reduced vs. Preserved Ejection Fraction
per: Christopher J. Charles, et al.
Publicat: (2020-10-01)

Real‐world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction
per: Jenni Huusko, et al.
Publicat: (2020-06-01)

Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction
per: Bence Hegyi, et al.
Publicat: (2022-12-01)

Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction
per: Heidi Budde, et al.
Publicat: (2022-07-01)

The Prognostic Value of Anemia in Patients with Preserved, Mildly Reduced and Recovered Ejection Fraction
per: Anita Pintér, et al.
Publicat: (2022-02-01)

Small Heart Size and Premature Death in 366,484 Individuals With Normal Ejection Fraction
per: Stephanie J. Rowe, BBiomed, MD, et al.
Publicat: (2025-01-01)

Sex differences in mortality and hospitalization in heart failure with preserved and mid-range ejection fraction: a systematic review and meta-analysis of cohort studies
per: You Deng, et al.
Publicat: (2024-01-01)

Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum
per: Karolina Andrzejczyk, et al.
Publicat: (2024-06-01)

Independent predictors of developing pulmonary hypertension in heart failure with reduced versus preserved ejection fraction
per: Alaa Roushdy, et al.
Publicat: (2017-07-01)

Age‐stratified profiles and outcomes of patients with heart failure with preserved ejection fraction
per: Shinsuke Yamanaka, et al.
Publicat: (2024-08-01)

Hydrogen Sulfide as a Potential Therapy for Heart Failure—Past, Present, and Future
per: Kyle B. LaPenna, et al.
Publicat: (2021-03-01)

Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy
per: Natasha L. Patel‐Murray, et al.
Publicat: (2024-07-01)

Incidence and risk factors of heart failure with preserved ejection fraction in elderly patients with hypertension
per: Min Chen, et al.
Publicat: (2024-12-01)

Effects of different exercise modalities on cardiac dysfunction in heart failure with preserved ejection fraction
per: David Bode, et al.
Publicat: (2021-06-01)

Therapeutic implications of statins in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction: a review of current literature [version 1; peer review: 2 approved]
per: Chanavuth Kanitsoraphan, et al.
Publicat: (2021-01-01)